Faruqi & Faruqi, LLP is Seeking More Cash for the Shareholders of BioClinica, Inc. (BIOC)
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NasdaqGM: BIOC) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to a holding company controlled by JLL Partners, Inc., a leading private equity firm, in an all-cash deal valued at approximately $123 million. Under the terms of the proposed transaction, BioClinica’s stockholders will receive $7.25 in cash for each share of BioClinica’s common stock they own, while according to Yahoo! Finance, at least one financial analyst has set a price target of $9.00 for BioClinica. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote.
The investigation focuses on whether BioClinica’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of BioClinica’s shareholders.
If you own common stock in BioClinica and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.